ReviewFuture microbiology2012
Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea.
Review in Future microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 202 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
202 citing papers in PubMed, 1 synthesis or guideline pooled it, 424 citations in OpenAlex.
- Wild-Type Gyrase A Genotype of Neisseria gonorrhoeae Predicts In Vitro Susceptibility to Ciprofloxacin: A Systematic Review of the Literature and Meta-Analysis.Sexually transmitted diseases · 2017Pooled it
- Single-Dose Pharmacokinetics, Excretion, and Metabolism of Zoliflodacin, a Novel Spiropyrimidinetrione Antibiotic, in Healthy Volunteers.Antimicrobial agents and chemotherapy · 2019Trial
- Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose-Ranging, Single-Oral Dose Evaluation.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Trial
- Genomic analysis ofMicrobiology spectrum · 2026Article
- Rise ofAntimicrobial agents and chemotherapy · 2026Article
- Surgical Management of Gonococcal Septic Arthritis: A Case Series and Literature Review.Journal of orthopaedic case reports · 2026Article
- Inhibition ofmBio · 2026Article
- Antimicrobial Resistance: A Bibliometric Review of Patient Health, Mechanisms, and Therapeutic Strategies.Pathogens (Basel, Switzerland) · 2026Review
- Identification of the cannabinoid receptor 1 antagonist, ibipinabant, as a potent inhibitor ofAntimicrobial agents and chemotherapy · 2026Article
- Structural insights into zinc piracy by Neisseria gonorrhoeae to overcome nutritional immunity.Structure (London, England : 1993) · 2026Article
- First Study on Antimicrobial Susceptibility and Molecular Epidemiology ofInfection and drug resistance · 2026Article
- Vaginal Microbiota Dysbiosis and Infections: A Comprehensive Review of Microbial and Therapeutic Perspectives.International journal of women's health · 2026Review
- Article
- Engineering multifunctional surface topography to regulate multiple biological responses.Biomaterials · 2025Review
- Coordinated Transcriptional Increases in Cell Wall Synthesis Genes in Neisseria gonorrhoeae Lacking the Lytic Transglycosylase, ltgA.Current microbiology · 2025Article
- Beyond behavioural change: prioritising structural solutions to control bacterial sexually transmitted infections.EClinicalMedicine · 2025Review
- Global burden of female infertility attributable to sexually transmitted infections and maternal sepsis: 1990-2021 and projections to 2050.Scientific reports · 2025Article
- Article
- Article
- Antimicrobial Resistance in Curable Sexually Transmitted Infections.Current HIV/AIDS reports · 2025Review
142 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The new superbug Neisseria gonorrhoeae has retained resistance to antimicrobials previously recommended for first-line treatment and has now demonstrated its capacity to develop resistance to the extended-spectrum cephalosporin, ceftriaxone, the last remaining option for first-line empiric treatment of gonorrhea. An era of untreatable gonorrhea may be approaching, which represents an exceedingly serious public health problem. Herein, we review the evolution, origin and spread of antimicrobial resistance and resistance determinants (with a focus on extended-spectrum cephalosporins) in N. gonorrhoeae, detail the current situation regarding verified treatment failures with extended-spectrum cephalosporins and future treatment options, and highlight essential actions to meet the large public health challenge that arises with the possible emergence of untreatable gonorrhea. Essential actions include: implementing action/response plans globally and nationally; enhancing surveillance of gonococcal antimicrobial resistance, treatment failures and antimicrobial use/misuse; and improving prevention, early diagnosis and treatment of gonorrhea. Novel treatment strategies, antimicrobials (or other compounds) and, ideally, a vaccine must be developed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.